John C. Gallagher

article 2018

Long-Term Outcomes of Elagolix in Women With Endometriosis

Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…

article 2017

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

·doi:10.1056/nejmoa1700089

Copyright Â© 2017 Massachusetts Medical Society. BACKGROUND Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, …

rct 2017

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

New England Journal of Medicine ·doi:10.1056/NEJMoa1700089

BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…

article 2005

DMPA-SC 104 has significantly less impact on bone mineral density than leuprolide acetate in patients with endometriosis

·doi:10.1016/j.contraception.2005.06.027

1977

Prospective trial of oestrogen and calcium in postmenopausal women.

British medical journal ·doi:10.1136/bmj.2.6090.789

In a prospective trial in 72 postmenopausal women to compare the effects on bone loss of no treatment, treatment with oestrogen, and treatment with calcium the women were followed up for at least two years and examined densitometrically and…